Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer

ESMO Open ◽  
2021 ◽  
Vol 6 (5) ◽  
pp. 100254
G. Mountzios ◽  
E. Samantas ◽  
K. Senghas ◽  
E. Zervas ◽  
J. Krisam ◽  
2020 ◽  
Vol 2020 (4-5) ◽  
Naoko Miura ◽  
Taichi Matsubara ◽  
Shinkichi Takamori ◽  
Naoki Haratake ◽  
Ryo Toyozawa ◽  

Abstract The transformation of adenocarcinoma to small cell lung cancer has been reported as acquisition of resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. We here report a patient who presented histologically confirmed transformation of adenocarcinoma to small cell lung cancer after treatment with immune checkpoint inhibitor. A 65-year-old man was treated with pembrolizumab as first-line therapy and achieved temporarily a stable disease with progression after six cycles of this agent. At that stage, a transbronchial biopsy showed small cell lung cancer, and he was found to have high serum concentrations of neuron-specific enolase despite concentrations of numerous tumor markers, including neuron-specific enolase, having been within normal limits at the time of presentation. The patient thereafter was treated as a small cell carcinoma patient using cisplatin plus irinotecan and amrubicin.

2019 ◽  
Vol 10 (3) ◽  
pp. 526-532 ◽  
Yuki Katayama ◽  
Tadaaki Yamada ◽  
Keiko Tanimura ◽  
Akihiro Yoshimura ◽  
Takayuki Takeda ◽  

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e21147-e21147 ◽  
Hiromi Watanabe ◽  
Toshio Kubo ◽  
Kiichiro Ninomiya ◽  
Kenichiro Kudo ◽  
Daisuke Minami ◽  

Sign in / Sign up

Export Citation Format

Share Document